Rapid Novor, Inc.
Rapid Novor is a leading company in antibody and protein sequencing, discovery, and characterization. They focus on next-generation protein sequencing technologies to enable the discovery and development of novel reagents, diagnostics, and therapeutics. With a mission to decode immunity and advance life sciences, they provide innovative services such as monoclonal and polyclonal antibody sequencing, epitope mapping, and AAV vector characterization. Their global presence includes offices in Canada, Europe, and the USA, and they have sequenced over 10,000 antibodies, contributing significantly to biomedical research and drug development. They also offer analytical characterization services for biologics, including antibody affinity and avidity analysis using advanced SPR technology.
Industries
Nr. of Employees
medium (51-250)
Rapid Novor, Inc.
Kitchener, Ontario, Canada, North America
Products
Cloud-based proteomics sequencing and identification software
Software platform for processing LC‑MS/MS data to support protein identification and de novo sequence assembly in cloud-hosted workflows.
External multiple myeloma blood test (laboratory assay)
Clinical laboratory assay offered via an external program for detection and monitoring related to multiple myeloma.
Cloud-based proteomics sequencing and identification software
Software platform for processing LC‑MS/MS data to support protein identification and de novo sequence assembly in cloud-hosted workflows.
External multiple myeloma blood test (laboratory assay)
Clinical laboratory assay offered via an external program for detection and monitoring related to multiple myeloma.
Services
Monoclonal antibody protein sequencing (de novo)
Determination of full-length monoclonal antibody amino-acid sequences from protein samples without requiring DNA or cell lines; supports reagent continuity and sequence recovery.
Polyclonal antibody sequencing for discovery
Sequencing and deconvolution of antigen-enriched polyclonal serum or antibody mixtures to identify multiple candidate antibodies for recombinant production and testing.
HDX-MS epitope mapping
Hydrogen–deuterium exchange mass-spectrometry mapping to identify antibody binding sites, characterize conformational changes, and provide medium-to-high resolution epitope localization.
Binding kinetics and interaction analysis (SPR)
Real-time, label-free SPR kinetic profiling (including localized/nanotechnology-enhanced SPR) to determine kon, koff and KD, perform epitope binning, quantify avidity in polyclonal samples, and support vaccine or immunogenicity assessments.
Antibody and protein characterization (MS-based)
Comprehensive mass-spectrometry characterization including peptide mapping, intact-mass analysis, glycan and PTM profiling, disulfide mapping, sequence-variant analysis and drug–antibody ratio measurement.
Recombinant antibody expression and small-scale production
Recombinant expression and delivery of antibodies and fragments for validation, binding assays, and downstream characterization following sequence recovery.
Monoclonal antibody protein sequencing (de novo)
Determination of full-length monoclonal antibody amino-acid sequences from protein samples without requiring DNA or cell lines; supports reagent continuity and sequence recovery.
Polyclonal antibody sequencing for discovery
Sequencing and deconvolution of antigen-enriched polyclonal serum or antibody mixtures to identify multiple candidate antibodies for recombinant production and testing.
HDX-MS epitope mapping
Hydrogen–deuterium exchange mass-spectrometry mapping to identify antibody binding sites, characterize conformational changes, and provide medium-to-high resolution epitope localization.
Binding kinetics and interaction analysis (SPR)
Real-time, label-free SPR kinetic profiling (including localized/nanotechnology-enhanced SPR) to determine kon, koff and KD, perform epitope binning, quantify avidity in polyclonal samples, and support vaccine or immunogenicity assessments.
Antibody and protein characterization (MS-based)
Comprehensive mass-spectrometry characterization including peptide mapping, intact-mass analysis, glycan and PTM profiling, disulfide mapping, sequence-variant analysis and drug–antibody ratio measurement.
Recombinant antibody expression and small-scale production
Recombinant expression and delivery of antibodies and fragments for validation, binding assays, and downstream characterization following sequence recovery.
Expertise Areas
- Antibody discovery from serum and polyclonal repertoires
- Mass spectrometry-based proteomics and de novo protein sequencing
- Epitope mapping and structural characterization using HDX-MS
- Affinity and avidity analysis and kinetic profiling by SPR
Key Technologies
- De novo protein sequencing (LC-MS/MS)
- Hydrogen–Deuterium Exchange Mass Spectrometry (HDX-MS)
- Ion mobility mass spectrometry (IMS)
- Surface plasmon resonance (SPR), including localized/nanotechnology-enhanced SPR